Sandoz's Enbrel biosim hits its sought-after equivalence mark in psoriasis


Novartis’s Sandoz is aiming to bring a biosimilar of Amgen anti-TNF giant, Enbrel, to market. And it just rolled out efficacy data that could help it get there.

Thursday, the generics behemoth announced that its copycat had met its primary endpoint in a psoriasis trial, posting comparable efficacy to Enbrel by hitting the equivalence mark on the Psoriasis Area and Severity Index after 12 weeks. The incidence of adverse events was comparable at that point, too, Sandoz said.

The data make up part of a package that’s already been accepted for review by the FDA and European Medicines Agency, according to the company. It’s hoping to snag a green light in all of Enbrel’s approved indications--including psoriasis and rheumatoid arthritis--to have the best shot of nabbing a piece of the $5.10 billion in U.S. sales that Enbrel raked in last year.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

And the company already accomplished the feat once. Last March, the FDA approved Zarxio--a copy of Amgen’s Neupogen--to treat all of Neupogen’s indications, though the med didn’t launch until September thanks to legal tussling between the two companies.

Amgen, for its part, doesn’t want to see another of its major meds come under biosimilar attack--especially before it can launch some of its own biosimilar prospects. Partner Pfizer, which markets Enbrel overseas, has already had that misfortune: In January, European regulators approved an Enbrel knockoff from Samsung Bioepis, to be sold by Biogen and rolled out gradually across the EU countries, along with Norway, Iceland and Liechtenstein.

Of course, biosimilar launches are a newer concept in the U.S., which has so far only seen Zarxio’s. And Sandoz, for one, has already felt the effects of a slower market. While Novartis blamed broader generics-industry trends for weak Sandoz Q4 sales, Bernstein analyst Ronny Gal suggested at the time that slow biosimilar development and uptake was to blame, and that Sandoz’ biosimilar push--along with a corresponding de-emphasis on “simple generics”--had created a gap in launches.

- read Sandoz's release 

Special Report: Top 20 generics companies by 2014 revenue - Novartis - Sandoz

Related Articles:
Novartis' Sandoz aims for 5 biosim launches by 2020
Big Enbrel beat, lower expenses help Amgen top Q1 forecasts
Don't blame industry trends for Sandoz's slide, analyst says. But biosimilars? Maybe
Big question for Pfizer: Will Enbrel's EU biosim bring on the pain?
Novartis targets Amgen's Enbrel with second biosimilar app
Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do?
Amgen's Neupogen won't face Novartis biosim till September: court
Novartis gets bragging rights on first U.S. biosim. But will its Neupogen copy sell?

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.